

Williams Michael J PhD  
 Form 4  
 April 29, 2011

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 Williams Michael J PhD

2. Issuer Name and Ticker or Trading Symbol  
 IDEXX LABORATORIES INC /DE [IDXX]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
 ONE IDEXX DRIVE  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 04/28/2011

\_\_\_\_ Director  
 Officer (give title below)  
 \_\_\_\_ 10% Owner  
 \_\_\_\_ Other (specify below)  
 Corporate Vice President

WESTBROOK, ME 04092

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	Price	
Common Stock	04/28/2011		M		7,000	A \$ 28.655	16,154 <sup>(1)</sup> D
Common Stock	04/28/2011		M		3,844	A \$ 38.335	19,998 D
Common Stock	04/28/2011		M		1,678	A \$ 38.335	21,676 D
Common Stock	04/28/2011		S		12,522	D \$ 80.8954	9,154 <sup>(2)</sup> D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	\$ 28.655	04/28/2011		M	7,000	<sup>(3)</sup> 02/02/2015	Common Stock	7,000
Non-Qualified Stock Option (right to buy)	\$ 38.335	04/28/2011		M	3,844	<sup>(4)</sup> 02/13/2013	Common Stock	3,844
Incentive Stock Option (right to buy)	\$ 38.335	04/28/2011		M	1,678	<sup>(5)</sup> 02/13/2013	Common Stock	1,678

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Williams Michael J PhD ONE IDEXX DRIVE WESTBROOK, ME 04092			Corporate Vice President	

## Signatures

John B. Rogers, Attorney-in-Fact for Michael J. Williams, PhD  
04/29/2011

\_\_\_\_\_  
\*\*Signature of Reporting Person

\_\_\_\_\_  
Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Edgar Filing: Williams Michael J PhD - Form 4

- (1) Includes 89 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 03/31/2011.

The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from

- (2) \$80.83 to \$80.95, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- (3) Grant of options to buy shares of common stock becomes exercisable as to 2,720 shares on 02/03/2006, 02/03/2007 and 2/3/2008, and the remaining 1,646 shares on 02/03/2009.
- (4) Grant of options to buy shares of common stock becomes exercisable as to 1,106 shares on 02/14/2007, 1,104 shares on 02/14/2008 and 02/14/2009, and the remaining 530 shares on 02/14/2010.
- (5) Grant of options to buy shares of common stock becomes exercisable as to 574 shares on 02/14/2010 and the remaining 1,104 shares on 02/14/2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.